Skip to content
DataLookout
Menu

NCT07468500

Real World Adherence of PCSK9 Targeted Therapy

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words Show 6 more changesShow less
    • Completed without a posted recruiting period
    • Final enrollment: 942 participants (planned 3600)
    • Primary completion date changed from estimate of Jul 30, 2026 to May 29, 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 30, 2026 to Feb 10, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Notable Eligibility criteria shortened, about 38 words
    • Start date: Mar 15, 2026 to Mar 30, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Medication adherence at 12 months : proportion of days covered (PDC) within a period that the patient is persistent
Timeframe: 12 months

Secondary (4)

Proportion of patients with good adherence
Number of patients by demographic category
Time to discontinuation
Proportion of patients receiving LLTs

Arms and interventions

exposure group

patients who initiated inclisiran as their first treatment

control group

patients who initiated evolocumab as their first treatment

Sites

1 site in 1 country

  • Novartis Investigative SiteTokyo, Japan